Precision Medicine will need to get out of the pharma silo that is based on symptoms

Welcome to the digital era of biology (and to this modest blog I started in early 2005).

To cure many diseases, like cancer or cystic fibrosis, we will need to target genes (mutations, for ex.), not organs! I am convinced that the future of replacement medicine (organ transplant) is genomics (the science of the human genome). In 10 years we will be replacing (modifying) genes; not organs!

Anticipating the $100 genome era and the P4™ medicine revolution. P4 Medicine (Predictive, Personalized, Preventive, & Participatory): Catalyzing a Revolution from Reactive to Proactive Medicine.

After low-cost airlines (Ryanair, Easyjet ...) comes "low-cost" participatory medicine. Some of my readers have recently christened this long-lasting, clumsy attempt at e-writing of mine "THE LOW-COSTE INNOVATION BLOG". I am an
early adopter of scientific MOOCs. My name's Catherine Coste. I've earned myself four MIT digital diplomas: 7.00x, 7.28x1, 7.28.x2 and 7QBWx. Instructor of 7.00x: Eric Lander PhD.

Upcoming books: Airpocalypse, a medical thriller (action taking place in Beijing) 2017; Jesus CRISPR Superstar, a sci-fi -- French title: La Passion du CRISPR (2018).

I love Genomics. Would you rather donate your data, or... your vital organs?

Audio files on this blog are Windows files ; if you have a Mac, you might want to use VLC ( to read them.

Concernant les fichiers son ou audio (audio files) sur ce blog : ce sont des fichiers Windows ; pour les lire sur Mac, il faut les ouvrir avec VLC (


Qui aurait cru qu'Autodesk se lancerait dans le bioprinting ! Je me demande ce que Dassault va faire...
"Organovo and Autodesk Team Up to Develop Bioprinting Software for Easy Tissue Engineering" : read here.
"Organovo, a leader in bioprinting with life science research devices already on the market, has partnered with Autodesk, the maker of the ubiquitous AutoCAD drafting suite. They aim to create specialty printing software for Organovo’s bioprinters.
Organovo’s NovoGen MMX bioprinters have unique abilities and limitations, so software that will be used to design and print living tissue must take these details into account. We’re hoping that, much like the 3D printer revolution that’s supposedly about to commence, this announcement foreshadows a similar bioprinting revolution in the life sciences.
From the announcement:
'Autodesk is an excellent partner for Organovo in developing new software for 3D bioprinters,' said Keith Murphy, Chairman and Chief Executive Officer at Organovo. 'This relationship will lead to advances in bioprinting, including both greater flexibility and throughput internally, and the potential long-term ability for customers to design their own 3D tissues for production by Organovo.'
'Bioprinting has the potential to change the world,' said Jeff Kowalski, Senior Vice President and Chief Technology Officer at Autodesk. 'It’s a blend of engineering, biology and 3D printing, which makes it a natural for Autodesk. I think working with Organovo to explore and evolve this emerging field will yield some fascinating and radical advances in medical research.'" (Source).

Aucun commentaire: